Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

80.26 -1.24 (-1.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 Next >
1 Cash-Heavy Stock That Stand Out and 2 to Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
Q1 Earnings Highs And Lows: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Let’s dig into the relative performance of LeMaitre (NASDAQ:LMAT) and its peers as we unravel the now-completed Q1 surgical equipment & consumables - specialty earnings season. 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Why LeMaitre (LMAT) Shares Are Sliding Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 12.2% in the afternoon session after the company reported weak first quarter 2025 results with a significant miss on full-year EPS... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings Scheduled For May 1, 2025
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
In-Depth Examination Of 4 Analyst Recommendations For LeMaitre Vascular
Via Benzinga
Analyst Scoreboard: 4 Ratings For LeMaitre Vascular
Via Benzinga
LeMaitre’s (NASDAQ:LMAT) Q1: Beats On Revenue, Guides for Strong Full-Year Sales
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 12% year on year to $59.87 million. Guidance for next... 
Via StockStory
A Look at LeMaitre Vascular's Upcoming Earnings Report
Via Benzinga
Earnings To Watch: LeMaitre (LMAT) Reports Q1 Results Tomorrow
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
1 Profitable Stock with Impressive Fundamentals and 2 to Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Navigating 4 Analyst Ratings For LeMaitre Vascular
Via Benzinga
Q4 Earnings Highlights: LeMaitre (NASDAQ:LMAT) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at LeMaitre (NASDAQ:LMAT) and the best and... 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
3 Healthcare Stocks Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & Consumables - Specialty Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - specialty stocks fared in... 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Why LEMAITRE VASCULAR INC (NASDAQ:LMAT) qualifies as a quality stock.
A fundamental analysis of (NASDAQ:LMAT): Why Quality Investors May Find LEMAITRE VASCULAR INC (NASDAQ:LMAT) Attractive. 
Via Chartmill
2 Reasons to Avoid LMAT and 1 Stock to Buy Instead
Over the past six months, LeMaitre’s shares (currently trading at $83.18) have posted a disappointing 10.5% loss while the S&P 500 was down 4.1%. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks Supply Chain
Exposures Supply Chain US Equities
Winners And Losers Of Q4: Integra LifeSciences (NASDAQ:IART) Vs The Rest Of The Surgical Equipment & Consumables - Specialty Stocks
Looking back on surgical equipment & consumables - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Integra LifeSciences (NASDAQ:IART) and its peers. 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
Q4 Earnings Review: Surgical Equipment & Consumables - Specialty Stocks Led by Intuitive Surgical (NASDAQ:ISRG)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Intuitive... 
Via StockStory
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Supply Chain
LeMaitre (NASDAQ:LMAT) Misses Q4 Sales Targets, Stock Drops 11%
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 14% year on year to $55.72 million. Next quarter’s revenue guidance of... 
Via StockStory
What To Expect From LeMaitre’s (LMAT) Q4 Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year
ResMed also boasts a superb 96 EPS Rating out of 99, putting it in the top 4% of all companies for recent and long-term profit growth. 
Via Investor's Business Daily
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
This Synopsys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
LMAT Stock Earnings: LeMaitre Vascular Beats EPS, Beats Revenue for Q2 2024
LMAT stock results show that LeMaitre Vascular beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Staar Surgical Stock Earns RS Rating Upgrade
On Thursday, lens maker Staar Surgical stock had its Relative Strength (RS) Rating upgraded to 87 from 77. 
Via Investor's Business Daily
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.